The FDA is moving to fast-track the review of certain psychedelic drugs, including psilocybin, for mental health treatment. The number of drugs or studies involved is reported to be three, with some outlets specifying that the FDA has issued vouchers to companies to aid in the review process. The exact timeline for the review and potential approval is unclear, with one outlet suggesting the drugs could be available as early as this summer.